74 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
our net operating loss carryforwards and certain other tax attributes may be limited.
We may fail to comply with privacy and data security … be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (“Confidential Data”) used … would qualify as “personal data,” “personal information” (or similar term) under the Privacy Laws (as defined below); and (vii) any other piece
8-K
EX-10.1
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
, availability, privacy and security of all sensitive, confidential or regulated data (“Confidential Data”) used or maintained in connection … ,” “personal information” (or similar term) under the Privacy Laws (as defined below); and (vii) any other piece of information that alone, or combined
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
and certain other tax attributes may be limited.
We may fail to comply with privacy and data security regulations.
We may fail to comply … parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.
Any third parties
POS AM
g1aysmyl pbe55d3
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
nvyfx
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
y6xsxtbhaw5zl1v l451
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
g7xf5zg9eh1cv328p
5 Feb 24
Entry into a Material Definitive Agreement
7:36am